How promising are HIV-1-based virus-like particles for medical applications
New approaches aimed at identifying patient-specific drug targets and addressing unmet clinical needs in the framework of precision medicine are a strong motivation for researchers worldwide. As scientists learn more about proteins that drive known diseases, they are better able to design promising...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2022.997875/full |
| _version_ | 1811226979034202112 |
|---|---|
| author | Sofia A. Martins Joana Santos Rúben D. M. Silva Cátia Rosa Sandra Cabo Verde Sandra Cabo Verde João D. G. Correia João D. G. Correia Rita Melo |
| author_facet | Sofia A. Martins Joana Santos Rúben D. M. Silva Cátia Rosa Sandra Cabo Verde Sandra Cabo Verde João D. G. Correia João D. G. Correia Rita Melo |
| author_sort | Sofia A. Martins |
| collection | DOAJ |
| description | New approaches aimed at identifying patient-specific drug targets and addressing unmet clinical needs in the framework of precision medicine are a strong motivation for researchers worldwide. As scientists learn more about proteins that drive known diseases, they are better able to design promising therapeutic approaches to target those proteins. The field of nanotechnology has been extensively explored in the past years, and nanoparticles (NPs) have emerged as promising systems for target-specific delivery of drugs. Virus-like particles (VLPs) arise as auspicious NPs due to their intrinsic properties. The lack of viral genetic material and the inability to replicate, together with tropism conservation and antigenicity characteristic of the native virus prompted extensive interest in their use as vaccines or as delivery systems for therapeutic and/or imaging agents. Owing to its simplicity and non-complex structure, one of the viruses currently under study for the construction of VLPs is the human immunodeficiency virus type 1 (HIV-1). Typically, HIV-1-based VLPs are used for antibody discovery, vaccines, diagnostic reagent development and protein-based assays. This review will be centered on the use of HIV-1-based VLPs and their potential biomedical applications. |
| first_indexed | 2024-04-12T09:33:46Z |
| format | Article |
| id | doaj.art-a49086422d83446a86ff5070c060bb3f |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-04-12T09:33:46Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-a49086422d83446a86ff5070c060bb3f2022-12-22T03:38:17ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882022-10-011210.3389/fcimb.2022.997875997875How promising are HIV-1-based virus-like particles for medical applicationsSofia A. Martins0Joana Santos1Rúben D. M. Silva2Cátia Rosa3Sandra Cabo Verde4Sandra Cabo Verde5João D. G. Correia6João D. G. Correia7Rita Melo8Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalDepartamento de Engenharia e Ciências Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalDepartamento de Engenharia e Ciências Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, PortugalNew approaches aimed at identifying patient-specific drug targets and addressing unmet clinical needs in the framework of precision medicine are a strong motivation for researchers worldwide. As scientists learn more about proteins that drive known diseases, they are better able to design promising therapeutic approaches to target those proteins. The field of nanotechnology has been extensively explored in the past years, and nanoparticles (NPs) have emerged as promising systems for target-specific delivery of drugs. Virus-like particles (VLPs) arise as auspicious NPs due to their intrinsic properties. The lack of viral genetic material and the inability to replicate, together with tropism conservation and antigenicity characteristic of the native virus prompted extensive interest in their use as vaccines or as delivery systems for therapeutic and/or imaging agents. Owing to its simplicity and non-complex structure, one of the viruses currently under study for the construction of VLPs is the human immunodeficiency virus type 1 (HIV-1). Typically, HIV-1-based VLPs are used for antibody discovery, vaccines, diagnostic reagent development and protein-based assays. This review will be centered on the use of HIV-1-based VLPs and their potential biomedical applications.https://www.frontiersin.org/articles/10.3389/fcimb.2022.997875/fullvirus-like particlesHIV-1-based virus-like particlesmedical applicationsvaccinesdrug delivery |
| spellingShingle | Sofia A. Martins Joana Santos Rúben D. M. Silva Cátia Rosa Sandra Cabo Verde Sandra Cabo Verde João D. G. Correia João D. G. Correia Rita Melo How promising are HIV-1-based virus-like particles for medical applications Frontiers in Cellular and Infection Microbiology virus-like particles HIV-1-based virus-like particles medical applications vaccines drug delivery |
| title | How promising are HIV-1-based virus-like particles for medical applications |
| title_full | How promising are HIV-1-based virus-like particles for medical applications |
| title_fullStr | How promising are HIV-1-based virus-like particles for medical applications |
| title_full_unstemmed | How promising are HIV-1-based virus-like particles for medical applications |
| title_short | How promising are HIV-1-based virus-like particles for medical applications |
| title_sort | how promising are hiv 1 based virus like particles for medical applications |
| topic | virus-like particles HIV-1-based virus-like particles medical applications vaccines drug delivery |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2022.997875/full |
| work_keys_str_mv | AT sofiaamartins howpromisingarehiv1basedviruslikeparticlesformedicalapplications AT joanasantos howpromisingarehiv1basedviruslikeparticlesformedicalapplications AT rubendmsilva howpromisingarehiv1basedviruslikeparticlesformedicalapplications AT catiarosa howpromisingarehiv1basedviruslikeparticlesformedicalapplications AT sandracaboverde howpromisingarehiv1basedviruslikeparticlesformedicalapplications AT sandracaboverde howpromisingarehiv1basedviruslikeparticlesformedicalapplications AT joaodgcorreia howpromisingarehiv1basedviruslikeparticlesformedicalapplications AT joaodgcorreia howpromisingarehiv1basedviruslikeparticlesformedicalapplications AT ritamelo howpromisingarehiv1basedviruslikeparticlesformedicalapplications |